商品名：Vetmedin
Pimobendan is both a positive inotrope and a vasodilator. The vasodilator effects occur via inhibition of phosphodiesterase III. Phosphodiesterase III is the enzyme that degrades cyclic adenosine monophosphate (cAMP); therefore, its action is to increase intracellular concentrations of cAMP. There may be some inhibition of phosphodiesterase V in the pulmonary circulation. The inotropic effects of pimobendan are attributed to its action as a calcium sensitizer rather than the phosphodiesterase inhibition. By acting as a calcium sensitizer, it increases the interaction of troponin C with contrac
Pimobendan is indicated for use in dogs for treatment of CHF. It has been used in dogs with either valvular insufficiency or cardiomyopathy. It is considered by many cardiologists as an essential initial treatment for dilated cardiomyopathy in dogs. Pimobendan 615 P When used in dogs, it has improved signs of heart failure and increased survival. When used in dogs, it may be administered with diuretics and angiotensin- converting enzyme (ACE) inhibitors. In trials in North America, pimobendan showed significant improvement compared to placebo in dogs treated with an ACE inhibitor and a diureti
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
犬產品、法域、疾病階段與診斷門檻不同，且貓無核准適應症；schema 尚不能完整表達 product+stage+phenotype+formulation 前，calculator、處方與貓 raw dose fail closed。
DRUGAPI 劑量審查引用的獸醫官方標示（各標示只適用於其產品、物種與法域，不可互換）
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。
fecal